The objective of this study was to investigate the bioequivalence of Mylan nitrofurantoin monohydrate/macrocrystals capsules to Procter & Gamble Macrobid® capsules following a single, oral 100 mg (1 x 100 mg) dose under fed conditions...
Date First Received: November 19, 2009
Last Updated: November 19, 2009
Verified by: Mylan Pharmaceuticals, November 2009
Clinical Trial Phase: Phase 1 | Start Date: July 2002
Overall Status: Completed
Estimated Enrollment: 80
Brief Summary
Official Title: “Single-Dose Food In Vivo Bioequivalence Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules (100 mg; Mylan) and Macrobid® Capsules (100 mg; Procter & Gamble) in Healthy Volunteers.”
Condition Keyword(s):
The objective of this study was to investigate the bioequivalence of Mylan nitrofurantoin monohydrate/macrocrystals capsules to Procter & Gamble Macrobid® capsules following a single, oral 100 mg (1 x 100 mg) dose under fed conditions.
Study Type: Interventional
Study Design: Other, Randomized, Open Label, Crossover Assignment, Bio-equivalence Study
Study Primary Completion Date: August 2002
Intervention(s) in this Clinical Trial
- Drug: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
- Drug: Macrobid® Capsules 100 mg
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
- Active Comparator: 2
- Macrobid® Capsules 100 mg
Outcome Measures for this Clinical Trial
Primary Measures
- The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.
- Time Frame: blood collection through 28 hours
Safety Issue?: No
- Time Frame: blood collection through 28 hours
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- healthy, adult subjects, 18 years and older
- able to swallow medication
Exclusion Criteria:
- institutionalized subjects
- history of any significant disease
- use of any prescription or OTC medications within 14 days of start of study
- received any investigational products within 30 days prior to start of study
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: Mylan Pharmaceuticals
Overall Clinical Trial Officials and Contacts
Thomas S Clark, M.D. Principal Investigator Kendle International Inc.
Additional Information
Information obtained from ClinicalTrials.gov on February 04, 2010
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01018342
Study ID Number: NITF-0256
ClinicalTrials.gov Identifier: NCT01018342
Health Authority: United States: Institutional Review Board
Mylan Pharmaceuticals Inc. - Clinical Trial Results
Recalls, Market Withdrawals and Safety Alerts
Medwatch, FDA Safety Information and Adverse Event Reporting Program
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.